Login to Your Account



FDA Briefing Docs: Calcitonin Cancer Risk 'Appears Plausible'

By Jennifer Boggs
Managing Editor

Friday, March 1, 2013

Briefing documents released ahead of Tuesday's FDA advisory meeting to discuss the risk-benefit profile of calcitonin-containing drugs in osteoporosis said the cancer risk associated with the polypeptide hormone "appears plausible" and "cannot be ignored," signaling another potential blow to the drug class.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription